ライフサイエンスコーパス: oncofetal

1 eric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeuti

2 Oncofetal Ag (OFA) is a 44-kDa glycoprotein expressed du

3 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intrinsic immunoregulatory properti

4 alpha-fetoprotein (AFP) is an oncofetal Ag that is highly expressed in abnormalities o

5 During tumor development in mice and humans, oncofetal Ag/immature laminin receptor (OFA/iLRP)-specif

6 r metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens.

7 The oncofetal antigen 5T4 is expressed in more than 90% of c

8 ese novel observations demonstrate that this oncofetal antigen can serve as an effective tumor reject

9 The oncofetal antigen Claudin 6 (CLDN6) is highly and specif

10 CAR T cells targeting glypican-1 (GPC1), an oncofetal antigen expressed in pancreatic cancer.

11 acid (Neu5Gc), which was long considered an oncofetal antigen in humans.

12 This oncofetal antigen is also expressed by hepatocytes in ce

13 The oncofetal antigen receptor tyrosine kinase orphan recept

14 3 and bivalently binds claudin 6 (CLDN6), an oncofetal antigen that is absent from normal adult tissu

15 Lex is an oncofetal antigen which appears on human gastric epithel

16 deaminated sialic acids KDN (2), a potential oncofetal antigen, and N-acetylneuraminic acid (Neu5Ac,

17 telomerase reverse transcriptase, G250, and oncofetal antigen, but not against self-antigens express

18 N-Glycolyneuraminic acid, a human oncofetal antigen, was found at all sites of all three c

19 ssessing the Lewisx determinant, which is an oncofetal antigen.

20 viral antigens, tumour-associated antigens, oncofetal antigens and shared neoantigens.

21 uitable for clinical testing, and credential oncofetal antigens as a promising class of targets for C

22 The amplified cells produce sialylated oncofetal carbohydrate antigens that function as recepto

23 The peptides encoded by the rat liver oncofetal cDNA TA1 and the human lymphocyte activation g

24 Elevated expression of the oncofetal cell surface heparan sulfate proteoglycan, gly

25 ns with high levels of the glycosaminoglycan oncofetal chondroitin sulfate (ofCS), are abundantly exp

26 Oncofetal chondroitin sulfate (ofCS), which distinctivel

27 sis with one of these products confirmed the oncofetal expression of transcripts related to TuAg.1/pE

28 The oncofetal fibronectin (B-FN) isoform is present in vesse

29 paid to the deposit of collagen, we identify oncofetal fibronectin (FN) as a major and obligate compo

30 ) TGF-beta treatment caused up-regulation of oncofetal fibronectin (onfFN), which is defined by mAb F

31 such as carcinoembryonic antigens (CEA) and oncofetal fibronectin, become reexpressed in malignant t

32 ROR1 has characteristics of an oncofetal gene and is expressed in undifferentiated embr

33 This bivalent epigenetic control of oncofetal gene expression in cancer cells may offer nove

34 The oncofetal gene SALL4, a marker of a subtype of hepatocel

35 fector T cell (Teff) ratio and expression of oncofetal genes (GPC3, AFP).

36 development, suggesting that let-7-regulated oncofetal genes (LOG) may become reexpressed in cancer c

37 ion embryonic program that encompasses known oncofetal genes as well as oncogenes not previously asso

38 ncovers a miRNA-repressed network containing oncofetal genes Imp1, Imp2, and Imp3 (Imp1-3) that is up

39 subgroup of hHCCs, with shared activation of oncofetal genes including Igf2, correlating with CpG hyp

40 -expression of ductal progenitor markers and oncofetal genes.

41 Polysialic acid is an oncofetal glycopolymer, added to the glycans of a small

42 Human carcinoembryonic antigen (CEA) is an oncofetal glycoprotein overexpression of which by gastro

43 ryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose overexpression by human car

44 The recognition of oncofetal H type 1 and type 1 LacNAc on OC by mAb-A4 is

45 Here, we find that the oncofetal HMGA2 gene is aberrantly reexpressed in many t

46 Expression of SLU7 and that of the adult and oncofetal isoforms of HNF4a, driven by its promoter 1 (P

47 tures of maturing hepatocytes expressing the oncofetal marker, alpha-fetoprotein.

48 pseudogene that may display properties of an oncofetal master regulator in human cancers.

49 The oncofetal mRNA-binding protein IGF2BP1 and the transcrip

50 This enhanced plasticity is initiated by oncofetal (OnF) reprogramming, driven by YAP and AP-1, w

51 multifunctional RNA-binding protein with an oncofetal pattern of expression shown to be implicated i

52 2BP1) is an mRNA-binding protein that has an oncofetal pattern of expression.

53 We show that the oncofetal protein 5T4 is expressed on tumor-initiating c

54 r the diagnosis and management of HCC, is an oncofetal protein expressed in a majority of HCCs but ra

55 Cripto-1 (CR1) is an oncofetal protein involved in EGF/TGFbeta signal transdu

56 Gamma-globin, an oncofetal protein overexpressed by clonogenic JMML cells

57 The RNA-binding protein IMP-3 is an oncofetal protein overexpressed in many human malignanci

58 The multiple functions of the oncofetal protein survivin are dependent on its selectiv

59 actor 2 mRNA-binding protein-1 (IMP-1) is an oncofetal protein that binds directly to and stabilizes

60 SALL4 is an oncofetal protein that is expressed in the human fetal l

61 e type 3 iodothyronine deiodinase (D3) is an oncofetal protein that is rarely expressed in adult life

62 RBMY is a novel oncofetal protein that plays a key role in attenuating g

63 rowth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poo

64 This localization requires the oncofetal protein ZBP1 (Zipcode binding protein 1), whic

65 CRD-BP also appears to be an oncofetal protein, based upon its expression during mamm

66 Thus, IMP-3 is considered to be an oncofetal protein.

67 ancer cases, and the CRD-BP appears to be an oncofetal protein.

68 transformed cell lines suggests CRD-BP is an oncofetal protein.

69 pression; and high coordinated expression of oncofetal proteins and stem-cell markers, while low-risk

70 We biochemically defined an oncofetal regulon of 15 factors connected to LIN28 throu

71 CRISPR knockout of LIN28B-an oncofetal RNA-binding protein exerting diverse effects v

72 We aimed to investigate whether IMP3, an oncofetal RNA-binding protein, can be used as a biomarke

73 lted from neonatal-specific expression of an oncofetal RNA-binding protein, IGF2BP3, which prevented

74 GF2 mRNA through phosphorylation of IMP2, an oncofetal RNA-binding protein.

75 ing proteins (IGF2BPs), are highly conserved oncofetal RNA-binding proteins (RBPs) that regulate RNA

76 CRD-BP/IGF2BP1 has been characterized as an "oncofetal" RNA binding protein typically highly expresse

77 t is Fibronectin Extra Domain-B (Fn-EDB), an oncofetal splice variant of a major extracellular matrix

78 Similarly, we found that normal and oncofetal splice variants of fibronectin, the primary EC

79 The oncofetal stem/progenitor cell marker NOPE is expressed

80 break immune tolerance to ROR1, which is an oncofetal surface antigen and survival-signaling recepto

81 ithelial cells that express MUC1 bearing the oncofetal Thomsen-Friedenreich antigen (Galbeta1,3 GalNA

82 One such microRNA target gene is the oncofetal transcription factor Plagl2, which regulates e

83 -cell responses against a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4), which have bee